Top Story

CDC includes ‘homelessness’ as indication for hepatitis A vaccine

February 15, 2019

Ascletis, 3-V Biosciences raise $18 million for phase 2 NASH therapy

February 15, 2019
3-V Biosciences has entered an exclusive license agreement with Ascletis Pharma for Ascletis to develop, manufacture and commercialize 3-V Biosciences’…
In the Journals

Anastomotic biliary complications post-LT linked to 7 comorbid factors

February 14, 2019
Researchers identified seven significant risk factors for the development of anastomotic biliary complications following liver transplantation in high-acuity patients…

Echosens, NASHNET collaborate for real-world NAFLD screening study

February 14, 2019
Echosens announced a pilot study in collaboration with the NASH Network designed to appropriately identify patients with progressive nonalcoholic fatty liver disease…
In the Journals Plus

Fatty liver increases diabetes risk for adults without obesity

February 14, 2019
Nonalcoholic fatty liver disease is an independent risk factor for diabetes development in adults without obesity, according to findings published in Nutrition
More Headlines »

Risky Business: Prophylaxis and Treatment of Cytomegalovirus in the Transplantation Setting

This activity is supported by educational grants from Merck & Co., Inc. and Shire.

Cytomegalovirus (CMV) is a common herpes virus that affects 50% to 80% of the US population. Disease from reactivation…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Resource Centers
International Liver Congress

International Liver Congress

Meeting News

VIDEO: Gilead reports phase 2 safety, efficacy of GS-9674 for NASH

November 27, 2018
More »
Current Issues Current Issues
View the Current Issue
HCV Next